Validation of lower risk mortality profile in pediatric febrile neutropenia during cancer chemotherapy;Criterios de bajo riesgo de mortalidad en niños con neutropenia y fiebre durante la quimioterapia por cancer

Medicina

Volumn 61, Issue 1, 2001, Pages 63-66

  Paganini, Hugo R ^a   Brieshcke, Teresa Rodriguez ^a   Zubizarreta, Pedro ^a   Latella, Antonio ^a   Firpo, Veronica ^a   Fernandez, Cristina ^a   Armada, Ariel ^a   Casimir, Lidia ^a   Debbag, Roberto ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

Cancer chemotherapy; Fever and neutropenia; Risk factors

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHILD HOSPITALIZATION; CHILDHOOD MORTALITY; DRUG EFFICACY; FEBRILE NEUTROPENIA; HUMAN; INFANT; INTRAVENOUS CATHETER; MAJOR CLINICAL STUDY; RISK FACTOR; TREATMENT FAILURE; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FEVER; HUMANS; INFANT; MALE; NEOPLASMS; NEUTROPENIA; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 0035102509     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infections in patients with acute leukemia. Ann Intern Med 1966; 64: 328-39.
2. Bodey GP. Overview of the problem of infections in the immunocompromised host. Am J Med 1985; 79 (Suppl): 56-61.
3. Rolston KVI, Rubenstein EB, Freifeld A. Early empiric antibiotic therapy for febrile neutropenia patients at low risk. Infect Dis Clin of North Am 1996; 10: 223-237.
4. Hughes WT, Armstrong D, Bodey GP, et al. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997; 25: 551-73.
5. Talcott JA, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988; 148: 2561-8.
6. Lucas KG, Brown AE, Armstrong D, et al. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 1996; 77: 791-8.
7. Bash RO, Katz JA, Cash JV, et al. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 1994; 74: 189-96.
8. Griffin TC, Buchanan G. Hematologic predictors of bone marrow recovery in neutropenic patients hospitalized for fever: implications for discontinuation of antibiotics and early discharge from the hospital. J Pediatr 1992; 121: 28-33.
9. Klaasen RJ, Goodman R, Ba Pham et al. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000; 18: 1012-
10. Paganini H, Bologna R, Debbag R., et al. Neutropenia and fever in child in one single institution in Argentina. Pediatr Hematol Oncol 1998; 5: 1-9.
11. Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999; 86: 126-34.
12. Isenberg HD, Baron EJ, D' Amato, et al. Recommendations for the isolation of bacteria from clinical specimens. In: Balows A., Hausler WK, Herrmann KL, Isenberg HD., Shadomy HK (ed): Manual of clinical microbiology. American Society for Microbiology, Washington DC, 1991; 216-21.
13. Centers for Disease Control: National nosocomial infection study site definitions manual. Centers for Disease Control , Atlanta, GA, 1972; 82-4.
14. Winfried V, Cometta A, de Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999; 341: 312-8.
15. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341: 305-11.
16. Finberg RW. Fever and neutropenia. How to use a new treatment strategy. N Engl J Med 1999; 341: 362-3.
17. Klaasen RJ, Allen U, Doyle JJ. Randomized placebo-controlled trial of oral antibiotics in low risk paediatric oncology patients with fever and neutropenia. J Pediatr Hematol Oncol 1999; 21: 334 (# 474).
18. Buchanan GR. Approach to treatment of the febrile cancer patients with low-risk neutropenia. Hematology/oncology Clin North Am 1993, 5: 919-35.
19. Paganini H, Gomez S, Sarkis C, y col. Eficacia clínica de ceftriaxona más amikacina en el tratamiento empírico de niños neutropénicos febriles de bajo riesgo de mortalidad. Medicina Infantil 1998; V: 244-8.